Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is obse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Ruella, Marco, Barrett, David M., Kenderian, Saad S., Shestova, Olga, Hofmann, Ted J., Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F., Melenhorst, Jan J., Morrissette, Jennifer J.D., Christian, David A., Hunter, Christopher A., Kalos, Michael, Porter, David L., June, Carl H., Grupp, Stephan A., Gill, Saar
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096828/
https://ncbi.nlm.nih.gov/pubmed/27571406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87366
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados